CERE News and Press, Ceres Inc. From 07/02/21

Shares of Cerevel Therapeutics ([[CERE]] -13.1%) are sharply down in afternoon trading after the company priced a $350M equity offering of 14M shares are $25 per share.The closing date is July 7.Underwriters have an a 30-day option to purchase an additional 2.1M shares.However, Cerevel shares...

The stock of Cerevel Therapeutics Holdings (NASDAQ: CERE) is under pressure in response to a secondary offering the company priced this morning. Investors unhappy about the dilutive effect of the offering pushed the stock 11.3% lower as of 12:42 p.m. on Friday. On Tuesday, share...

Gainers: Sequential Brands Group (SQBG) +88%.Alector (ALEC) +50%.TAT Technologies (TATT) +43%.Marin Software (MRIN) +41%.Overseas Shipholding (OSG) +35%.Staffing 360 Solutions (STAF) +31%.Bridgeline Digital (BLIN) +31%.IDT (IDT) +21%.Nortech Systems (NSYS) +19%.Ocean Power Technologies (OPTT)...

Cerevel Therapeutics (CERE) has priced its public offering of 14M common shares at $25.00/share, for expected gross proceeds of ~$350M.Underwriters' over-allotment is an additional 2.1M shares.Closing date is July 7. J.P. Morgan Securities, Goldman Sachs, Jefferies, and Stifel, Nicolaus &...

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of ...

Altimmune (ALT) -33% Altimmune to scrap COVID-19 vaccine program after "disappointing" results.Panbela Therapeutics (PBLA) -26% after secures $10M capital raiseMarin Software (MRIN) -20%.Check-Cap (CHEK) -17% after announcing $35M registered direct offering.Qumu (QUMU...

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that is has commenced an underwritten public offering of 14,000,000 shares of its common stoc...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Cerevel Therapeutics Sees Positive Results for CVL-231 in Phase 1b Clinical Trial ” Cerevel Therapeutics (NASDAQ: CERE) surged over 59% in premarke...

babyrhino/iStock via Getty Images Shares of Cerevel Therapeutics ([[CERE]] +128.8%) have more than doubled today after the company this morning positive positive results on its novel phase 1b candidate for schizophrenia, CVL-231. The company plans to advance the candidate into phase 2 as well...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerevel Therapeutics (NASDAQ: CERE ) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing ...